• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives 3-alkylindoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles 3-alkylindoles

Introduction to (6-Fluoro-1H-indol-3-yl)methanamine (CAS No. 887582-19-6)

(6-Fluoro-1H-indol-3-yl)methanamine, identified by its Chemical Abstracts Service (CAS) number 887582-19-6, is a significant compound in the realm of pharmaceutical and biochemical research. This compound belongs to the indole derivatives family, which has garnered considerable attention due to its diverse biological activities and potential therapeutic applications. The presence of a fluorine atom at the 6-position of the indole ring enhances its pharmacological properties, making it a valuable scaffold for drug discovery.

The structural motif of (6-Fluoro-1H-indol-3-yl)methanamine consists of an indole core linked to an aminomethyl group. This configuration allows for multiple functionalization possibilities, enabling the synthesis of various analogs with tailored biological effects. The fluorine substituent, in particular, is known to improve metabolic stability and binding affinity, which are critical factors in drug development.

In recent years, there has been growing interest in indole derivatives as potential candidates for treating a range of diseases, including cancer, neurological disorders, and infectious diseases. The fluorinated indole derivatives have shown promise in preclinical studies due to their ability to modulate key biological pathways. For instance, research has indicated that compounds with a similar structural framework may inhibit enzymes involved in tumor growth and angiogenesis.

One of the most compelling aspects of (6-Fluoro-1H-indol-3-yl)methanamine is its versatility in medicinal chemistry. Researchers have leveraged this compound as a building block to develop novel molecules with enhanced pharmacokinetic profiles. The introduction of fluorine at the 6-position of the indole ring has been particularly effective in improving oral bioavailability and reducing susceptibility to metabolic degradation.

Recent advancements in computational chemistry have further accelerated the discovery process for compounds like (6-Fluoro-1H-indol-3-yl)methanamine. Molecular modeling studies have helped predict the binding interactions between this compound and target proteins, providing insights into its mechanism of action. These simulations have been instrumental in optimizing lead structures before they enter preclinical testing.

The synthesis of (6-Fluoro-1H-indol-3-yl)methanamine involves multi-step organic reactions, often requiring precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions, have been employed to construct the indole core efficiently. These techniques not only streamline the synthetic route but also minimize unwanted byproducts.

In the context of drug development, the fluorine atom in (6-Fluoro-1H-indol-3-yl)methanamine plays a crucial role in modulating drug-receptor interactions. Fluorine substitution can alter electronic properties, leading to improved binding affinity and selectivity. This feature has been exploited in the design of kinase inhibitors, where fluorinated indoles have demonstrated superior efficacy compared to their non-fluorinated counterparts.

Current research is exploring the potential applications of (6-Fluoro-1H-indol-3-yl)methanamine in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Studies suggest that indole derivatives may protect against oxidative stress and inflammation, two key pathological processes in these conditions. The fluorine atom's ability to enhance molecular stability makes this compound an attractive candidate for further investigation.

The pharmaceutical industry has recognized the importance of fluorinated indoles and is investing heavily in their development. Companies are focusing on optimizing synthetic routes to produce these compounds at scale while maintaining high purity standards. This effort is driven by the promising preclinical data showing their therapeutic potential.

Future directions in research may involve exploring analogs of (6-Fluoro-1H-indol-3-yl)methanamine with different substituents at various positions on the indole ring. Such modifications could lead to novel compounds with enhanced potency and reduced side effects. Additionally, investigating the role of fluorine in modulating pharmacokinetic properties will continue to be a key area of focus.

In conclusion, (6-Fluoro-1H-indol-3-yl)methanamine (CAS No. 887582-19-6) represents a promising compound with significant potential in pharmaceutical applications. Its unique structural features and biological activities make it a valuable asset in drug discovery efforts aimed at treating various diseases. As research progresses, this compound is likely to play an increasingly important role in developing next-generation therapeutics.

• 1196146-75-4((6-Fluoroquinolin-3-yl)methanamine)
• 392-13-2(5-Fluoro-3-methylindole)
• 887582-26-5((7-Fluoro-1H-indol-3-yl)methanamine)
• 343-90-8(5-Fluorogramine)
• 101909-46-0(4-Fluorogramine)
• 113188-82-2((5-fluoro-1H-indol-3-yl)methanamine)
• 949535-35-7(7-fluoro-4-Quinolinemethanamine)
• 1011484-23-3(6-fluoro-3-methyl-1H-Indole)
• 343-93-1([(6-fluoro-1H-indol-3-yl)methyl]dimethylamine)
• 1334286-66-6(7-fluoro-1,4-dimethyl-9H-Carbazole)